1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novartis Eyes Broader Market As Pluvicto Hits Mark In Pivotal Second-Line mCRPC Trial

Peak Sales Estimates Could Increase

 
• By Ayisha Sharma

The major’s radioligand therapy has succeeded in an earlier line of prostate cancer therapy that presents a large market opportunity, but some observers are keen to see full data before raising their sales projections.  

Conceptual high tech power plant thermonuclear or nuclear reactor, including elements of fusion space stations, electricity production, microwave components.
Radioligand Therapies Can Deliver Radioactivity Directly To Cancer Cells • Source: Shutterstock

Novartis AG’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has met the primary endpoint in a pivotal second-line prostate cancer trial, sparking plans for a US filing that could significantly boost market opportunity, but some experts are awaiting full data before raising sales projections.

The Phase III PSMAfore trial set the radioligand therapy against standard-of-care androgen-receptor pathway inhibitor (ARPI) therapy in 469 people with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.